Applicant, as named in the Orange Book
Foldrx Pharms
Pfizer Inc · NYSE: PFE
Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings
Next listed expiry: Vyndamax on 31 Aug 2035. 1 products with live protection, 0 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Vyndamax NDA 212161 tafamidis | 31 Aug 2035 patent |
Recent events
- Vyndaqel · Enters 12-month window basis: patentListed date 19 Dec 2026Detected 24 Oct 2026